Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 735 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Biliary Diseases Clear all

Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer, Urothelial Carcinoma (UC), Cholangiocarcinoma, Mesothelioma, Gallbladder Cancer, Ovarian Cancer
Interventions: MDX2001; Drug
Lead sponsor: ModeX Therapeutics, An OPKO Health Company; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Denver, Colorado • Miami, Florida • Boston, Massachusetts + 3 more

Conditions: Cholangitis
Interventions: Ceftriaxone, Levofloxacin; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Interventions: nasal potential difference testing; Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 12 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Small Bowel Cancer, Colorectal Cancer, Appendiceal Cancer, Biliary Cancer, Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Oligoprogressive
Interventions: Ablative local therapy; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2039
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Liver Cirrhosis, Biliary
Interventions: S-adenosyl-methionine (SAMe) capsules; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alagille Syndrome
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
Interventions: High Dose Radiation (HDR) Brachytherapy, MRI, CT, PET Scan; Radiation · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diagnosis of a Pancreaticobiliary Disorder
Interventions: Endoscopy; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer, Periampullary Adenocarcinoma, Small Intestine Cancer
Interventions: erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin, laboratory biomarker analysis; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gastric Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Biliary Cancer
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Progressive Familial Intrahepatic Cholestasis
Interventions: Odevixibat; Drug
Lead sponsor: Albireo; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Sclerosing Cholangitis
Interventions: Not listed
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Aurora, Colorado • Miami, Florida • Bethesda, Maryland + 2 more

Conditions: Cholelithiasis
Interventions: General Anesthesia, Epidural Anesthesia; Procedure
Lead sponsor: Florida Hospital Tampa Bay Division; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Gallbladder Cancer, Liver Cancer, Bile Duct Cancer
Interventions: questionnaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar 10 mg, Placebo, Seladelpar 5 mg; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 40
States / cities: Chandler, Arizona • Little Rock, Arkansas • Palo Alto, California + 31 more

Conditions: Cholelithiasis
Interventions: Single site robotic chole, da Vinci Si Surgical System; Procedure · Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Interventions: derazantinib; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 8 more

Conditions: Cholestasis
Interventions: tauroursodeoxycholic acid; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 20 Days
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Jackson, Mississippi • Cincinnati, Ohio

Conditions: Primary Sclerosing Cholangitis
Interventions: Volixibat, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 34
States / cities: Coronado, California • Los Angeles, California • Sacramento, California + 26 more

Conditions: Extrahepatic Bile Duct Cancer, Liver Cancer
Interventions: fluorouracil, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Total Parenteral Nutrition-induced Cholestasis
Interventions: Omegaven IV lipid emulsion; Drug
Lead sponsor: Sivan Kinberg; Other
Eligibility: 2 Months to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus, Cancer of Liver, Cancer
Interventions: wet heparinzed suction, Microsieve, No heparin flush, No microsieve; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC), Urothelial Cancer, Nasopharyngeal Cancers
Interventions: AVZO-1418, Combination Agent 1, Combination Agent 2; Drug
Lead sponsor: Avenzo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 19
States / cities: Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms, Bladder Cancer
Interventions: Brigimadlin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 18
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 14 more

Search by objective public record fields.

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Antibiotics to Decrease Post ERCP Cholangitis

NPDT Evaluation in Children With CFTR and (PSC)

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

SAMe to Treat Biliary Cirrhosis Symptoms

Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review

A Study of Patients Receiving High-Dose Rate Brachytherapy

Advanced Imaging Registry for Diagnosing Pancreatico-biliary Disorders

Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Perception Prognosis, Goals of Treatment, and Communication

Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis

Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)

Comparing Epidural Versus General Anesthesia for LESS Cholecystectomies

Quality Of Life in Patients With Malignant Biliary Obstruction

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Single Site Robotic Cholecystectomy in Non Selected Patients

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer

Compassionate Use of Omegaven IV Fat Emulsion

Wet Heparinized Suction for Abdominal Cancer

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder